Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.51 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22803696 | 0.80 | NPC1 (0.67) | EPHX1NPC1RAB9AMAPTMAOA | |
| SCHEMBL22803968 | 0.80 | ESR1 (0.62) | EPHX1IDH1NPC1RAB9AMAPT | |
| SCHEMBL22803276 | 0.80 | IDH1 (0.52) | EPHX1IDH1NPC1RAB9AMAPT | |
| SCHEMBL31668688 | 0.79 | MAOA (0.66) | EPHX1NPC1RAB9AMAPTMAOA | |
| SCHEMBL30504231 | 0.79 | IDH1 (0.61) | EPHX1IDH1NPC1RAB9AMAPT | |
| SCHEMBL17664180 | 0.79 | IDH1 (0.61) | EPHX1IDH1NPC1RAB9AMAPT | |
| SCHEMBL22803273 | 0.78 | IDH1 (0.53) | EPHX1IDH1NPC1RAB9AMAPT | |
| SCHEMBL4000123 | 0.78 | TRPV1 (0.63) | IDH1NPC1RAB9AMAPTMAOA | |
| SCHEMBL4000115 | 0.78 | TRPV1 (0.63) | IDH1NPC1RAB9AMAPTMAOA | |
| SCHEMBL20360718 | 0.78 | NPC1 (0.48) | NPC1RAB9AMAPTTRPV1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | EPHX1 1188/4885IDH1 2467/4885NPC1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.